RF&L Wealth Management LLC Has $3.38 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

RF&L Wealth Management LLC trimmed its position in Eli Lilly and Company (NYSE:LLY) by 3.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,734 shares of the company’s stock after selling 150 shares during the period. Eli Lilly and Company makes up approximately 2.6% of RF&L Wealth Management LLC’s holdings, making the stock its 15th biggest holding. RF&L Wealth Management LLC’s holdings in Eli Lilly and Company were worth $3,381,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Everpar Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $1,845,000. International Assets Investment Management LLC raised its holdings in shares of Eli Lilly and Company by 5.3% in the fourth quarter. International Assets Investment Management LLC now owns 12,597 shares of the company’s stock valued at $7,343,000 after purchasing an additional 632 shares during the last quarter. Tennessee Valley Asset Management Partners acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $181,000. Tranquility Partners LLC raised its holdings in shares of Eli Lilly and Company by 5.2% in the fourth quarter. Tranquility Partners LLC now owns 856 shares of the company’s stock valued at $499,000 after purchasing an additional 42 shares during the last quarter. Finally, Waterfront Wealth Inc. raised its holdings in shares of Eli Lilly and Company by 2.1% in the fourth quarter. Waterfront Wealth Inc. now owns 1,157 shares of the company’s stock valued at $674,000 after purchasing an additional 24 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the transaction, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 92,563 shares of the firm’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the transaction, the insider now directly owns 98,556,247 shares in the company, valued at approximately $79,752,700,634.87. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the transaction, the chief accounting officer now owns 7,130 shares in the company, valued at $5,842,821.10. The disclosure for this sale can be found here. Insiders sold a total of 1,214,704 shares of company stock valued at $1,066,841,316 in the last quarter. 0.13% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms recently weighed in on LLY. Truist Financial reissued a “buy” rating and issued a $1,000.00 target price (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Argus raised their target price on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. Bank of America raised their target price on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research note on Monday, August 5th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and raised their target price for the company from $725.00 to $1,025.00 in a research note on Monday, August 12th. Two analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $956.88.

Eli Lilly and Company Trading Down 1.0 %

LLY stock traded down $9.46 during trading on Friday, hitting $922.12. The company had a trading volume of 2,364,894 shares, compared to its average volume of 3,096,824. The business has a 50-day moving average of $878.93 and a 200-day moving average of $806.28. Eli Lilly and Company has a one year low of $516.57 and a one year high of $966.10. The stock has a market cap of $876.39 billion, a PE ratio of 135.81, a PEG ratio of 1.81 and a beta of 0.41. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.56%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.